Aurora Cannabis Announces Fiscal 2025 Third Quarter Results
Aurora Cannabis (NASDAQ: ACB) reported strong fiscal Q3 2025 results with total net revenue of $88.2 million, up 37% YoY. The company achieved record-breaking performance across multiple metrics, including global medical cannabis net revenue of $68.1 million (up 51% YoY), net income of $31.2 million (up 282% YoY), and adjusted EBITDA of $23.1 million (up 316% YoY).
The company's international net revenue grew 112% and represented 60% of global medical cannabis revenue. The plant propagation segment increased 22% due to organic expansion. Aurora maintained a strong balance sheet with $180 million in cash and a debt-free cannabis business, except for $57.9 million in non-recourse debt related to Bevo Farms.
Medical cannabis contributed 77% of consolidated net revenue with a 74% adjusted gross margin. Consumer cannabis revenue decreased 15% to $9.9 million as the company prioritized its higher-margin medical cannabis business.
Aurora Cannabis (NASDAQ: ACB) ha riportato risultati solidi per il terzo trimestre fiscale 2025, con ricavi netti totali di $88,2 milioni, in aumento del 37% rispetto all'anno precedente. L'azienda ha ottenuto prestazioni record su più metriche, tra cui ricavi globali netti da cannabis medica di $68,1 milioni (in aumento del 51% rispetto all'anno precedente), un utile netto di $31,2 milioni (in aumento del 282% rispetto all'anno precedente) e un EBITDA rettificato di $23,1 milioni (in aumento del 316% rispetto all'anno precedente).
I ricavi netti internazionali dell'azienda sono aumentati del 112% e rappresentano il 60% dei ricavi globali da cannabis medica. Il segmento della propagazione vegetale è aumentato del 22% grazie all'espansione organica. Aurora ha mantenuto un solido bilancio con $180 milioni in contanti e un'azienda di cannabis senza debiti, ad eccezione di $57,9 milioni in debito non ricorrente legato a Bevo Farms.
La cannabis medica ha contribuito per il 77% ai ricavi netti consolidati, con un margine lordo rettificato del 74%. I ricavi dalla cannabis per consumatori sono diminuiti del 15% a $9,9 milioni poiché l'azienda ha dato priorità al suo business di cannabis medica ad alto margine.
Aurora Cannabis (NASDAQ: ACB) informó resultados sólidos para el tercer trimestre fiscal de 2025, con ingresos netos totales de $88,2 millones, un aumento del 37% en comparación con el año anterior. La compañía logró un rendimiento récord en múltiples métricas, incluidos los ingresos netos globales de cannabis medicinal de $68,1 millones (un aumento del 51% interanual), un ingreso neto de $31,2 millones (un aumento del 282% interanual) y un EBITDA ajustado de $23,1 millones (un aumento del 316% interanual).
Los ingresos netos internacionales de la compañía crecieron un 112% y representaron el 60% de los ingresos globales de cannabis medicinal. El segmento de propagación de plantas aumentó un 22% debido a la expansión orgánica. Aurora mantuvo un balance sólido con $180 millones en efectivo y un negocio de cannabis sin deudas, excepto por $57,9 millones en deuda no garantizada relacionada con Bevo Farms.
El cannabis medicinal contribuyó con el 77% de los ingresos netos consolidados, con un margen bruto ajustado del 74%. Los ingresos del cannabis para consumidores disminuyeron un 15% a $9,9 millones, ya que la compañía priorizó su negocio de cannabis medicinal de mayor margen.
오로라 캐너비스 (NASDAQ: ACB)는 2025 회계 연도 3분기 결과로 총 순수익이 8,820만 달러에 달하며, 전년 대비 37% 증가했다고 보고했습니다. 회사는 기록적인 성과를 달성했으며, 여기에는 전 세계 의료용 대마초 순수익이 6,810만 달러(전년 대비 51% 증가), 순이익 3,120만 달러(전년 대비 282% 증가), 조정 EBITDA 2,310만 달러(전년 대비 316% 증가)가 포함됩니다.
회사의 국제 순수익은 112% 증가했으며, 이는 전 세계 의료용 대마초 수익의 60%를 차지합니다. 식물 번식 부문은 유기적 확장 덕분에 22% 증가했습니다. 오로라는 1억 8천만 달러의 현금을 보유하고 있으며, Bevo Farms와 관련된 5,790만 달러의 비대출 부채를 제외하고는 부채가 없는 강력한 재무 상태를 유지하고 있습니다.
의료용 대마초는 통합 순수익의 77%를 차지하며, 조정된 총 마진은 74%입니다. 소비자 대마초 수익은 9,910만 달러로 15% 감소했으며, 이는 회사가 더 높은 마진을 기록하는 의료용 대마초 사업에 우선 순위를 두었기 때문입니다.
Aurora Cannabis (NASDAQ: ACB) a annoncé des résultats solides pour le troisième trimestre fiscal 2025, avec un chiffre d'affaires net total de 88,2 millions de dollars, en hausse de 37 % par rapport à l'année précédente. L'entreprise a réalisé une performance record sur plusieurs indicateurs, y compris un chiffre d'affaires net mondial de cannabis médical de 68,1 millions de dollars (en hausse de 51 % par rapport à l'année précédente), un bénéfice net de 31,2 millions de dollars (en hausse de 282 % par rapport à l'année précédente) et un EBITDA ajusté de 23,1 millions de dollars (en hausse de 316 % par rapport à l'année précédente).
Le chiffre d'affaires net international de l'entreprise a augmenté de 112 % et représentait 60 % du chiffre d'affaires mondial de cannabis médical. Le segment de la propagation des plantes a augmenté de 22 % grâce à une expansion organique. Aurora a maintenu un bilan solide avec 180 millions de dollars en espèces et une entreprise de cannabis sans dettes, à l'exception de 57,9 millions de dollars de dettes non remboursables liées à Bevo Farms.
Le cannabis médical a contribué à 77 % du chiffre d'affaires net consolidé, avec une marge brute ajustée de 74 %. Les revenus du cannabis à des fins récréatives ont diminué de 15 % pour atteindre 9,9 millions de dollars, l'entreprise ayant donné la priorité à son activité de cannabis médical à plus forte marge.
Aurora Cannabis (NASDAQ: ACB) meldete starke Ergebnisse für das dritte Geschäftsjahr 2025 mit einem Gesamtumsatz von 88,2 Millionen Dollar, was einem Anstieg von 37% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte rekordverdächtige Leistungen in mehreren Kennzahlen, darunter ein globaler Nettoumsatz von medizinischem Cannabis von 68,1 Millionen Dollar (ein Anstieg von 51% im Jahresvergleich), ein Nettogewinn von 31,2 Millionen Dollar (ein Anstieg von 282% im Jahresvergleich) und ein bereinigtes EBITDA von 23,1 Millionen Dollar (ein Anstieg von 316% im Jahresvergleich).
Der internationale Nettoumsatz des Unternehmens wuchs um 112% und machte 60% des globalen medizinischen Cannabisumsatzes aus. Der Bereich Pflanzenvermehrung nahm aufgrund organischer Expansion um 22% zu. Aurora hielt eine starke Bilanz mit 180 Millionen Dollar in bar und einem schuldenfreien Cannabisgeschäft, abgesehen von 57,9 Millionen Dollar an nicht rückzahlbarem Darlehen im Zusammenhang mit Bevo Farms.
Medizinisches Cannabis trug 77% zum konsolidierten Nettoumsatz bei, mit einer bereinigten Bruttomarge von 74%. Die Einnahmen aus Konsumcannabis sanken um 15% auf 9,9 Millionen Dollar, da das Unternehmen sein höher margiges Geschäft mit medizinischem Cannabis priorisierte.
- Record net income of $31.2 million, up 282% YoY
- Global medical cannabis revenue increased 51% to $68.1 million
- Adjusted EBITDA grew 316% to $23.1 million
- Generated positive free cash flow of $27.4 million
- Strong medical cannabis gross margins of 74%
- International revenue growth of 112%
- Debt-free cannabis business with $180 million cash position
- Consumer cannabis revenue declined 15% to $9.9 million
- Consumer cannabis gross margins decreased to 26% from 29% YoY
- Filing of preliminary base shelf prospectus for potential $250M securities issuance
Insights
Aurora Cannabis has delivered a transformative quarter that signals a successful pivot to a sustainable, profitable business model. The standout achievement is the
The international expansion strategy is particularly noteworthy, with international revenue accounting for
The achievement of positive free cash flow (
Aurora's Q3 results demonstrate successful market segmentation and strategic positioning in the global cannabis industry. The company's focus on medical cannabis markets, particularly in Europe and Australia, has proven prescient given the higher barriers to entry, more stable pricing and better margins compared to recreational markets. The
The plant propagation business through Bevo has emerged as a reliable growth driver, with revenue increasing
The preliminary base shelf prospectus filing for
NASDAQ | TSX: ACB
- Reports Total Net Revenue1 of
$88.2 Million 37% YoY, Including Record Net Revenue1 of$68.1 Million 51% YoY - Generates Record Net Income of
$31.2 Million 282% YoY, and Record Adjusted EBITDA1 of$23.1 Million 316% YoY - Achieves Target of Positive Free Cash Flow1 in Q3, Generating
$27.4 Million - Maintains Strong Balance Sheet with
$180 Million
"This quarter was record-breaking for Aurora, driven by all-time highs in global medical net revenue1, net income, adjusted EBITDA1, and free cash flow1. These achievements, along with our strong cash position and debt-free cannabis business, underscore Aurora's leadership in the global cannabis industry as we continue to set ourselves apart from our peers," said Miguel Martin, Executive Chairman and Chief Executive Officer for Aurora Cannabis.
"Our strong top-line performance and record adjusted EBITDA1 were mostly fueled by contributions from our global medical cannabis business. International net revenue1 grew
_________________________________________________________________________________________ |
1 This press release includes certain non-GAAP financial measures, which are intended to supplement, not substitute for, comparable GAAP financial measures. See "Non-GAAP Measures" below for reconciliations of non-GAAP financial measures to GAAP financial measures. |
2 Aurora's only remaining debt is non-recourse debt of |
Third Quarter 2025 Highlights
(Unless otherwise stated, comparisons are made between fiscal Q3 2025, Q2 2025, and Q3 2024 results and are in Canadian dollars)
Consolidated Revenue and Adjusted Gross Profit:
Total net revenue1 was
Consolidated adjusted gross margin before fair value adjustments1 was
Medical Cannabis:
Medical cannabis net revenue1 was
The increase in net revenue1 of
Adjusted gross margin before fair value adjustments1 on medical cannabis net revenue reached
Consumer Cannabis:
Aurora's consumer cannabis net revenue1 was
Adjusted gross margin before fair value adjustments1 on consumer cannabis net revenue1 was
Plant Propagation:
Plant propagation net revenue1 was wholly comprised of the Bevo business, and contributed
Adjusted gross margin before fair value adjustments1 on plant propagation revenue was
Selling, General and Administrative ("SG&A"):
Adjusted SG&A1 was
Net Income (Loss):
Net income from continuing operations for the three months ended December 31, 2024 was
Adjusted EBITDA:
Adjusted EBITDA1 increased
Fiscal Q4 2025 Expectations:
- Continued revenue growth across our cannabis business, supported by year over year growth in international medical cannabis.
- Seasonally higher revenues for plant propagation, in line with historical seasonal trends.
- Margins to hold strong and positive adjusted EBITDA to continue.
- Improved operating cash use will be supported by continued spend discipline on capex and expected revenue growth.
- Free cash flow is projected to be modestly positive due to continued revenue growth and improved operating cash use.
Subsequent Events:
Concurrently with filing of the Q3 Financials, the Company has filed a preliminary base shelf prospectus which, together with a corresponding registration statement to be filed with the United States Securities and Exchange Commission, when made final or effective, will replace the Company's existing base shelf prospectus that is due to expire on May 27, 2025 and will qualify the issuance of U.S.
Key Quarterly Financial Results
($ thousands, except Operational Results) | Three months ended | ||||||
December 31, 2024 | September 30, 2024 | $ Change | % Change | December 31, 2023(3) | $ Change | % Change | |
Financial Results | |||||||
Net revenue (1a) | 9 % | 37 % | |||||
Medical cannabis net revenue (1a) | 11 % | 51 % | |||||
Consumer cannabis net revenue (1a) | ( | (5 %) | ( | (15 %) | |||
Plant propagation revenue | 3 % | 22 % | |||||
Adjusted gross margin before FV adjustments on total net revenue (1b) | 65 % | 54 % | N/A | 11 % | 53 % | N/A | 12 % |
Adjusted gross margin before FV adjustments on cannabis net revenue (1b) | 67 % | 57 % | N/A |
| 56 % | N/A | 11 % |
Adjusted gross margin before FV adjustments on medical cannabis net revenue (1b) | 74 % | 68 % | N/A | 6 % | 63 % | N/A | 11 % |
Adjusted gross margin before FV adjustments on consumer cannabis net revenue (1b) | 26 % | 14 % | N/A | 12 % | 29 % | N/A | (3 %) |
Adjusted gross margin before FV adjustments on plant propagation net revenue (1b) | 40 % | 19 % | N/A | 21 % | 28 % | N/A | 12 % |
Adjusted SG&A expense(1d) | ( | (1 %) | 13 % | ||||
Adjusted EBITDA (1c) | 128 % | 316 % | |||||
Free cash flow (1e) | ( | 204 % | ( | 682 % | |||
Balance Sheet | |||||||
Working capital (1f) | 12 % | 12 % | |||||
Cannabis inventory and biological assets (2) | 19 % | 88 % | |||||
Total assets | 7 % | 5 % | |||||
(1) | These terms are defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the following sections for reconciliation of Non-GAAP Measures to the IFRS equivalent measure: | |
a. | Refer to the "Revenue" and "Cost of Sales and Gross Margin" section for a reconciliation of cannabis net revenue to the IFRS equivalent. | |
b. | Refer to the "Adjusted Gross Margin" section for reconciliation to the IFRS equivalent. | |
c. | Refer to the "Adjusted EBITDA" section for reconciliation to the IFRS equivalent. | |
d. | Refer to the "Operating Expenses" section for reconciliation to the IFRS equivalent. | |
e. | Refer to the "Liquidity and Capital Resources" section for a reconciliation to the IFRS equivalent. | |
f. | "Working capital" is defined as Current Assets less Current Liabilities as reported on the Company's Consolidated Statements of Financial Position. | |
(2) | Represents total biological assets and inventory, exclusive of merchandise, accessories, supplies, consumables and plant propagation biological assets. | |
(3) | Certain previously reported amounts have been adjusted to exclude the results of discontinued operations and adjusted for non-material prior period adjustments (refer to Note 2 in the condensed consolidated interim financial statements). |
Conference Call
Aurora will host a conference call today, Wednesday, February 5, 2025, to discuss these results. Miguel Martin, Chief Executive Officer, and Simona King, Chief Financial Officer, will host the call starting at 8:00 a.m. Eastern time | 6:00 a.m. Mountain Time. A question and answer session will follow management's presentation.
DATE: | Wednesday, February 5, 2025 |
TIME: | 8:00 a.m. Eastern Time | 6:00 a.m. Mountain Time |
WEBCAST: |
About Aurora Cannabis
Aurora is opening the world to cannabis, serving both the medical and consumer markets across
Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".
Forward Looking Statements
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the Company's Q3 FY2025 results, statements under the heading "Fiscal Q4 2025 Expectations", including as related to revenue growth and adjusted gross margins, revenue and gross profit in the plant propagation segment, and expectations for positive adjusted EBITDA and free cash flow, statements regarding the Company's continued commitment to strategic growth, operational excellence, and long-term sustained profitability, the filing of the Shelf Prospectus and availability of funds, as well as statements regarding the Company's conference call to discuss results.
These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the timing, magnitude and duration of potential new or increased tariffs imposed on goods imported from
The Company's AIF, MD&A and annual financial statements, which have been filed on SEDAR+ and with the SEC, are also available on the Company's website www.auroramj.com and shareholders may receive hard copies free of charge upon request by contacting aurora@icrinc.com.
Non-GAAP Measures
This news release contains reference to certain financial performance measures that are not recognized or defined under IFRS (termed "Non-GAAP Measures"). As a result, this data may not be comparable to data presented by other licensed producers of cannabis and cannabis companies. Non-GAAP Measures should be considered together with other data prepared in accordance with IFRS to enable investors to evaluate the Company's operating results, underlying performance and prospects in a manner similar to Aurora's management. Accordingly, these non-GAAP Measures are intended to provide additional information and to assist management and investors in assessing financial performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with IFRS. The information included under the heading "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" in the Company's management's discussion and analysis for the fiscal period ended December 31, 2024 (the "MD&A") is incorporated by reference into this news release. The MD&A is available on the Company's issuer profiles on SEDAR+ at www.sedarplus.com and on the SEC's EDGAR website at www.sec.gov.
Net Revenue, Adjusted Gross Profit and Margin
Net revenue, adjusted gross profit before FV adjustments, and adjusted gross margin before FV adjustments are Non-GAAP Measures and can be reconciled with revenue, gross profit and gross margin, the most directly comparable GAAP financial measures, respectively, as follows:
($ thousands) | Three months ended | Nine months ended | |||
December 31, 2024 | September 30, 2024(2) | December 31, 2023(2) | December 31, 2024 | December 31, 2023(3) | |
Medical cannabis net revenue(1) | |||||
Canadian medical cannabis net revenue | 27,295 | 26,269 | 25,797 | 80,681 | 76,619 |
International medical cannabis net revenue | 40,854 | 35,047 | 19,241 | 95,985 | 53,250 |
Total medical cannabis net revenue | 68,149 | 61,316 | 45,038 | 176,666 | 129,869 |
Consumer cannabis net revenue(1) | |||||
Consumer cannabis net revenue(1) | 9,912 | 10,422 | 11,623 | 31,867 | 36,725 |
Wholesale bulk cannabis net revenue(1) | 1,240 | 750 | 429 | 3,610 | 1,289 |
Total cannabis net revenue(1) | 79,301 | 72,488 | 57,090 | 212,143 | 167,883 |
— | |||||
Plant propagation revenue | 8,897 | 8,634 | 7,285 | 40,612 | 34,343 |
Total net revenue(1) | 88,198 | 81,122 | 64,375 | 252,755 | 202,226 |
(1) | Net revenue is a Non-GAAP Measure and is defined in the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. Refer to the "Cost of Sales and Gross Margin" section of this MD&A for a reconciliation to IFRS equivalent. |
(2) | Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Adjusted EBITDA
Adjusted EBITDA is a Non-GAAP Measure and can be reconciled with net income (loss), the most directly comparable GAAP financial measure, as follows:
($ thousands) | Three months ended | Nine months ended | |||
December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023(6) | |
Net income (loss) from continuing operations | 31,228 | 1,675 | (17,058) | 37,747 | (36,816) |
Income tax expense (recovery) | 841 | (1,072) | (67) | 2,626 | 157 |
Other income (expense) | 4,787 | (2,995) | (471) | (5,032) | (6,183) |
Share-based compensation | 1,657 | 4,468 | 2,839 | 9,144 | 9,688 |
Depreciation and amortization | 5,678 | 6,380 | 8,378 | 18,552 | 25,770 |
Acquisition costs | 819 | 991 | 1,567 | 2,811 | 2,356 |
Inventory and biological assets fair value and impairment adjustments | (28,311) | 529 | (491) | (40,130) | (8,600) |
Business transformation related charges (1) | 4,537 | 3,394 | 5,132 | 12,312 | 17,650 |
Out-of-period adjustments (2) | — | — | 613 | — | 1,421 |
Non-recurring items (3) | 1,855 | (3,248) | 5,107 | 80 | 5,990 |
Adjusted EBITDA (4) | 23,101 | 10,122 | 5,549 | 38,110 | 11,433 |
(1) | Business transformation related charges includes costs related to closed facilities, certain IT project costs, costs associated with the repurposing of Sky and Sun, severance and retention costs in connection with the business transformation plan, and costs associated with the retention of certain medical aggregators. Some prior period amounts have been adjusted for changes in presentation. |
(2) | Out-of-period adjustments reflect adjustments to net loss for the financial impact of transactions recorded in the current period that relate to prior periods. Some prior period amounts have been adjusted for changes in presentation. |
(3) | Non-recurring items includes one-time excise tax refunds, non-core adjusted wholesale bulk margins, inventory count adjustments resulting from facility shutdowns and inter-site transfers, litigation and non-recurring project costs. |
(4) | Adjusted EBITDA is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of the MD&A. Prior period comparatives were adjusted to include the adjustments for markets under development, business transformation costs and non-recurring charges related to non-core bulk cannabis wholesale to be comparable to the current period presentation. |
Adjusted SG&A
Adjusted SG&A is a Non-GAAP Measure and can be reconciled with sales and marketing and general and administrative expenses, the most directly comparable GAAP financial measure, as follows:
Three months ended | Nine months ended | ||||
($ thousands) | December 31, 2024 | September 30, 2024 | December 31, 2023(2) | December 31, 2024 | December 31, 2023(2) |
General and administration | 23,443 | 22,036 | 22,259 | 68,003 | 66,135 |
Sales and marketing | 13,077 | 13,721 | 12,106 | 40,822 | 37,387 |
Business transformation costs | (4,885) | (4,035) | (5,150) | (13,788) | (15,728) |
Out-of-period adjustments | — | — | 214 | — | (594) |
Non-recurring costs | (373) | — | (1,670) | (657) | (2,675) |
Adjusted SG&A (1) | 31,262 | 31,722 | 27,759 | 94,380 | 84,525 |
(1) | Adjusted SG&A is a Non-GAAP Measure and is not a recognized, defined, or standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
(2) | Certain previously reported amounts have been adjusted to exclude the results related to discontinued operations. |
Free Cash Flow
The table below outlines free cash flow for the periods ended:
Three months ended | Nine months ended | ||||
($ thousands) | December 31, 2024 | September 30, 2024 | December 31, 2023 | December 31, 2024 | December 31, 2023 |
Cash provided by (used in) operating activities from continuing operations before changes in non-cash working capital | 13,815 | 5,295 | (11,390) | 17,288 | (37,451) |
Changes in non-cash working capital | 15,805 | (29,588) | 7,566 | (3,101) | (5,206) |
Net cash provided by (used in) operating activities from continuing operations | 29,620 | (24,293) | (3,824) | 14,187 | (42,657) |
Less: maintenance capital expenditures(1) | (2,256) | (2,140) | (878) | (6,766) | (5,188) |
Free cash flow(2) | 27,364 | (26,433) | (4,702) | 7,421 | (47,845) |
(1) | Maintenance capital expenditures are comprised of costs to sustain facilities, machinery and equipment in working order to support operations and excludes discretionary investments for revenue growth. |
(2) | Free cash flow is a Non-GAAP Measure and is not a recognized, defined, or a standardized measure under IFRS. Refer to the "Cautionary Statement Regarding Certain Non-GAAP Performance Measures" section of this MD&A. |
Working Capital
Working capital is a Non-GAAP Measure and can be reconciled with total current assets and total current liabilities, the most directly comparable GAAP financial measure, as follows:
($ thousands) |
December 31, 2024 | Three months ended September 30, 2024 |
December 31, 2023 | |
Total current assets | 494,211 | 417,675 | 411,194 | |
Total current liabilities | (149,807) | (109,095) | (102,451) | |
Working capital(1) | 344,404 | 308,580 | 308,743 | |
(1) Working capital for the three months ended December 31, 2024 has been adjusted. Refer to discussion under "Liquidity and Capital Resources" section of the MD&A. |
View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-announces-fiscal-2025-third-quarter-results-302368291.html
SOURCE Aurora Cannabis Inc.
FAQ
What was Aurora Cannabis's (ACB) revenue growth in Q3 2025?
How much free cash flow did ACB generate in Q3 2025?
What was ACB's medical cannabis performance in Q3 2025?
Why did ACB's consumer cannabis revenue decline in Q3 2025?
What is ACB's cash position and debt status as of Q3 2025?
